Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Protocol
12-104
Full Title
Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer (GOG-0273)
Purpose

Chemotherapy may be associated with side effects, such as low blood counts. For this reason, some doctors may be reluctant to give the same chemotherapy to elderly patients that they give to younger patients because they may not be able to tolerate the side effects, particularly elderly patients with other health problems.

The purpose of this study is to see how well older women with ovarian, primary peritoneal, or fallopian tube cancer tolerate chemotherapy. The goal of the study is to see if patients’ ability to complete activities of daily living before treatment is correlated with their ability to tolerate chemotherapy, and to see how chemotherapy works in older women with cancer.

Participants will include women who will receive either carboplatin with paclitaxel and pegfilgrastim, or carboplatin alone. They will be asked to complete questionnaires about their health, well-being, and ability to complete activities of daily living before chemotherapy starts and 12 to 15 weeks after it starts. Patients will also have periodic blood tests. They will receive four cycles of chemotherapy, and if it is safe and beneficial, may continue to have additional treatment.

Eligibility

Participants will include English-speaking patients age 70 and older who will receive chemotherapy (carboplatin alone or with paclitaxel) for stage I-IV ovarian, primary peritoneal, or fallopian tube cancer. Patients may not have previously received chemotherapy for the cancer, but may have had surgery.

For more information about this study, please contact Dr. William Tew at 646-888-4220.

Disease(s)
Geriatrics
Ovarian Cancer
Related Diseases